The U.S. Food and Drug Administration approved Phathom Pharmaceuticals Inc.’s Voquezna Triple Pak (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and Voquezna Dual Pak (vonoprazan tablets, amoxicillin capsules) for the treatment of Helicobacter pylori infection in adults.
Private drug discovery company Cerevance reported positive clinical trial results for CVN424, an experimental treatment for Parkinson’s disease.
Merck announced that the company will lay off 170 people from Cambridge, Massachusetts-based Acceleron Pharma, which was acquired during November 2021 for about $11.5 billion.
Bayer will present a range of new clinical data at the American College of Cardiology’s 71st Annual Scientific Session (ACC.22), being held April 2-4, 2022, in Washington, D.C. Data from KERENDIA® (finerenone), a first-in-class nonsteroidal mineralocorticoid receptor antagonist (MRA)1 and asundexian, an investigational oral Factor XIa inhibitor2 will be presented at the meeting. These data highlight Bayer’s ongoing commitment to patients with cardiovascular (CV) and kidney diseases.
Novartis’ proposed drug for adults diagnosed with a certain type of advanced prostate cancer was given the green light for commercialization.
Bristol Myers Squibb’s Opdualag – a new, first-in-class, fixed-dose combination of nivolumab and relatlimab, administered as a single intravenous infusion – was approved by the U.S. Food and Drug Administration for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma.
A late-stage study of Gilead Sciences’ antibody-drug conjugate Trodelvy shows promise in slowing disease progression in some of the most common forms of breast cancer.
The U.S. Food and Drug Administration approved Immunocore’s Kimmtrak (tebentafusp-tebn) for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma (mUM).
BioSpace reviews the 10 biggest drug approvals of 2021, headlined by Biogen’s Aduhelm (aducanumab) as the first drug approved for Alzheimer’s disease in almost 20 years.
The U.S. Food and Drug Administration approved Novartis’ Leqvio (inclisiran), the first small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol (also known as bad cholesterol or LDL-C) with two doses a year, after an initial dose and one at three months.